Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hydroxysafflor Yellow A Attenuates Hydrogen Peroxide-Induced Oxidative Damage on Human Umbilical Vein Endothelial Cells.

Evidence-based complementary and alternative medicine : eCAM·2020
Same author

2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-Glucoside modulated human umbilical vein endothelial cells injury under oxidative stress.

The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology·2020
Same author

Evaluation of the impact of suspended particles on the UV absorbance at 254 nm (UV<sub>254</sub>) measurements using a submersible UV-Vis spectrophotometer.

Environmental science and pollution research international·2020
Same author

Ferulic acid (FA) protects human retinal pigment epithelial cells from H<sub>2</sub> O<sub>2</sub> -induced oxidative injuries.

Journal of cellular and molecular medicine·2020
Same author

SIRT1 Is the Target Gene for 2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-Glucoside Alleviating the HUVEC Senescence.

Frontiers in pharmacology·2020
Same author

Fast and effective biomedical named entity recognition using temporal convolutional network with conditional random field.

Mathematical biosciences and engineering : MBE·2020

Related Experiment Video

Updated: May 31, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

Caicun Zhou1, Laurent Greillier2, Geoffrey Liu3

  • 1Shanghai East Hospital, Shanghai.

The New England Journal of Medicine
|May 29, 2026
PubMed
Summary

Sunvozertinib significantly improves progression-free survival in advanced non-small-cell lung cancer (NSCLC) with EGFR exon 20 insertions compared to chemotherapy. This study highlights sunvozertinib

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: May 31, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

  • Oncology
  • Clinical Trials
  • Pharmacology

Background:

  • Sunvozertinib is approved for later-line treatment of advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
  • Efficacy and safety data for sunvozertinib as a first-line treatment for NSCLC are limited.

Purpose of the Study:

  • To evaluate the efficacy and safety of sunvozertinib compared to chemotherapy as a first-line treatment for advanced NSCLC patients with EGFR exon 20 insertion mutations.

Main Methods:

  • A Phase 3, international, randomized trial comparing sunvozertinib to chemotherapy (carboplatin-pemetrexed) in 324 patients with advanced nonsquamous NSCLC and EGFR exon 20 insertions.
  • Primary endpoint: progression-free survival (PFS) by blinded independent central review.
  • Secondary endpoints included overall survival, investigator-assessed PFS, objective response rate, and safety.

Main Results:

  • Sunvozertinib demonstrated significantly longer median PFS (10.3 months) versus chemotherapy (7.5 months) (HR, 0.65; P<0.001).
  • Objective response rate was higher with sunvozertinib (58.9%) compared to chemotherapy (31.1%).
  • Grade 3 or higher adverse events were more frequent with sunvozertinib (75.5%) than chemotherapy (56.7%), with increased serum creatine kinase, diarrhea, and anemia being most common.

Conclusions:

  • Sunvozertinib shows superior efficacy compared to chemotherapy as a first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations.